会计年度:2014-06-30收入分布
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 1、西药制剂产品 | 1,020,404,325.31 | 249,746,874.57 | 770,657,450.74 | 75.52 |
| 2、原料药 | 500,843,650.89 | 429,042,521.62 | 71,801,129.27 | 14.34 |
| 3、中药制剂 | 827,214,672.39 | 178,135,374.05 | 649,079,298.34 | 78.47 |
| 4、诊断试剂及设备 | 203,063,114.66 | 89,584,166.31 | 113,478,948.35 | 55.88 |
| 5、其他 | 6,826,332.20 | 7,381,115.41 | -554,783.21 | -8.13 |
| 促性激素 | 365,627,291.28 | 131,196,493.97 | 234,430,797.31 | 64.12 |
| 抗微生物药物 | 168,020,368.07 | 39,490,245.60 | 128,530,122.47 | 76.50 |
| 其他 | 204,668,145.90 | 38,380,351.66 | 166,287,794.24 | 81.25 |
| 西药制剂产品 | 1,020,404,325.31 | 249,746,874.57 | 770,657,450.74 | 75.52 |
| 消化道 | 202,699,817.49 | 22,266,882.78 | 180,432,934.71 | 89.01 |
| 心脑血管 | 79,388,702.57 | 18,412,900.56 | 60,975,802.01 | 76.81 |
|
会计年度:2013-12-31
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 促性激素 | 605,501,360.68 | 204,285,858.64 | 401,215,502.04 | 66.26 |
| 抗微生物药物 | 279,197,291.07 | 71,937,103.73 | 207,260,187.34 | 74.23 |
| 其他 | 280,466,696.95 | 44,280,038.54 | 236,186,658.41 | 84.21 |
| 其他(文山丽珠中药材销售) | 40,629,979.00 | 17,676,898.66 | 22,953,080.34 | 56.49 |
| 消化道 | 358,678,027.99 | 41,087,643.48 | 317,590,384.51 | 88.54 |
| 心脑血管 | 148,085,906.50 | 35,331,396.31 | 112,754,510.19 | 76.14 |
| 血液及造血系统药物 | 30,596,426.21 | 31,084,154.27 | -487,728.06 | -1.59 |
| 原料药 | 798,576,223.52 | 713,205,195.01 | 85,371,028.51 | 10.69 |
| 诊断试剂及设备 | 368,732,853.87 | 162,882,180.14 | 205,850,673.73 | 55.83 |
| 中药制剂 | 1,658,923,222.87 | 331,573,643.29 | 1,327,349,579.58 | 80.01 |
|
会计年度:2013-06-30
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 其中:促性激素 | 270,853,275.00 | 93,290,770.00 | 177,562,505.00 | 65.56 |
| 其中:抗微生物药物 | 133,415,459.00 | 38,257,257.00 | 95,158,201.00 | 71.32 |
| 其中:其他 | 134,222,932.00 | 36,503,201.00 | 97,719,732.00 | 72.80 |
| 其中:消化道 | 177,085,278.00 | 21,331,635.00 | 155,753,643.00 | 87.95 |
| 其中:心脑血管 | 72,477,673.00 | 17,181,393.00 | 55,296,280.00 | 76.29 |
| 西药制剂 | 788,054,617.00 | 206,564,256.00 | 581,490,361.00 | 73.79 |
| 原料药 | 397,815,397.00 | 349,888,613.00 | 47,926,784.00 | 12.05 |
| 诊断试剂及设备 | 175,836,535.00 | 82,174,063.00 | 93,662,471.00 | 53.27 |
| 中药制剂 | 791,562,123.00 | 161,538,368.00 | 630,023,755.00 | 79.59 |
|
会计年度:2012-12-31
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 促性激素 | 458,128,100.00 | 158,953,000.00 | 299,175,100.00 | 65.30 |
| 代理进口品种 | 2,433,900.00 | 425,100.00 | 2,008,800.00 | 82.53 |
| 抗微生物药物 | 273,858,600.00 | 87,718,600.00 | 186,140,000.00 | 67.97 |
| 其他 | 161,852,700.00 | 38,449,900.00 | 123,402,800.00 | 76.24 |
| 消化道 | 300,654,700.00 | 39,974,400.00 | 260,680,300.00 | 86.70 |
| 心脑血管 | 142,778,600.00 | 33,197,400.00 | 109,581,200.00 | 76.75 |
| 血液及造血系统药物 | 24,741,400.00 | 24,103,900.00 | 637,500.00 | 2.58 |
| 原料药 | 834,638,300.00 | 711,885,900.00 | 122,752,400.00 | 14.71 |
| 诊断试剂及设备 | 341,161,300.00 | 158,441,500.00 | 182,719,800.00 | 53.56 |
| 中药制剂 | 1,383,249,300.00 | 296,754,000.00 | 1,086,495,300.00 | 78.55 |
|
会计年度:2012-06-30
|
| 项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
| 促性激素 | 219,119,400.00 | 78,003,700.00 | 141,115,700.00 | 64.40 |
| 代理进口品种 | 2,424,600.00 | 423,600.00 | 2,001,000.00 | 82.53 |
| 抗微生物药物 | 141,216,400.00 | 46,602,000.00 | 94,614,400.00 | 67.00 |
| 其他 | 69,307,600.00 | 17,683,800.00 | 51,623,800.00 | 74.49 |
| 消化道 | 148,506,500.00 | 19,922,200.00 | 128,584,300.00 | 86.58 |
| 心脑血管 | 72,112,100.00 | 16,872,100.00 | 55,240,000.00 | 76.60 |
| 血液及造血系统药物 | 12,284,100.00 | 11,719,900.00 | 564,200.00 | 4.59 |
| 原料药 | 402,904,500.00 | 341,271,900.00 | 61,632,600.00 | 15.30 |
| 诊断试剂及设备 | 152,370,500.00 | 69,464,600.00 | 82,905,900.00 | 54.41 |
| 中药制剂 | 654,809,600.00 | 138,137,700.00 | 516,671,900.00 | 78.90 |
|
4/9 转到 
